| answer text |
<p>The National Institute for Health and Care Excellence (NICE) has published clinical
guidelines on a range of mental health topics, such as depression, anxiety and schizophrenia.
Clinical guidelines provide guidance on the treatment of patients across the care
pathway and each guideline recommends a number of treatments.<br> <br> Additionally,
the following technologies for the treatment of mental health and behavioural conditions
are recommended by NICE technology appraisal guidance:</p><p> </p><table><tbody><tr><td><p>Appraisal
Number</p></td><td><p>Year</p></td><td><p>Technology</p></td><td><p>Condition</p></td><td><p>Categorisation</p></td></tr><tr><td><p>TA59</p></td><td><p>2003</p></td><td><p>Electroconvulsive
therapy</p></td><td><p>Catatonia/ prolonged or severe manic episode</p></td><td><p>Optimised<sup>1</sup></p></td></tr><tr><td><p>TA098</p></td><td><p>2006</p></td><td><p>Atomoxetine</p></td><td><p>Attention
deficit hyperactivity disorder (ADHD)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA098</p></td><td><p>2006</p></td><td><p>Dexamfetamine</p></td><td><p>Attention
deficit hyperactivity disorder (ADHD)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA098</p></td><td><p>2006</p></td><td><p>Methylphenidate</p></td><td><p>Attention
deficit hyperactivity disorder (ADHD)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA213</p></td><td><p>2011</p></td><td><p>Aripiprazole</p></td><td><p>Schizophrenia
in people aged 15-17 years</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Donepezil</p></td><td><p>Alzheimer's
disease (mild to moderate)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Galantamine</p></td><td><p>Alzheimer's
disease (mild to moderate)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Rivastigmine</p></td><td><p>Alzheimer's
disease (mild to moderate)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Memantine</p></td><td><p>Alzheimer's
disease (moderate)</p></td><td><p>Optimised</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Memantine</p></td><td><p>Alzheimer's
disease (severe)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA292</p></td><td><p>2013</p></td><td><p>Aripiprazole</p></td><td><p>Moderate
to severe manic episodes in adolescents with bipolar disorder</p></td><td><p>Recommended</p></td></tr></tbody></table><p>
</p><p> </p><p> </p><p><em>Source</em>: National Institute for Health and Care Excellence</p><p>
</p><p> </p><p> </p><p><sup>1 </sup>The drug or technology is recommended for a smaller
subset of patients than originally stated by the marketing authorisation.</p><p> </p><p>
</p><p> </p><p>Patients have the right to drugs and treatments that have been recommended
by NICE technology appraisal guidance for use in the National Health Service, where
their doctor believes they are clinically appropriate.</p><p> </p><p> </p><p> </p><p>Details
of all NICE’s guidance on mental health and behavioural conditions can be found at:</p><p>
</p><p> </p><p> </p><p><a href="http://www.nice.org.uk/guidancemenu/conditions-and-diseases/mental-health-and-behavioural-conditions"
target="_blank">www.nice.org.uk/guidancemenu/conditions-and-diseases/mental-health-and-behavioural-conditions</a></p><p>
</p><p><strong> </strong></p><p> </p>
|
|
